Compare · head to head
Aclaris Therapeutics vs Medpaces
Medpaces ranks higher overall — 360 rank 96 vs 28.
Medpaces leads on Value (54 vs 42), Quality (83 vs 32), Growth (64 vs 45) and Safety (63 vs 45). Aclaris Therapeutics leads on Sentiment (62 vs 43).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Size | Small | Large |
| ISIN | US00461U1051 | US58506Q1094 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 28 | 96 |
| Value | 42 | 54 |
| Quality | 32 | 83 |
| Growth | 45 | 64 |
| Safety | 45 | 63 |
| Sentiment | 62 | 43 |
| Quality details | ||
| Profitability | 19 | 95 |
| Cash Truth | 46 | 71 |
Aclaris Therapeutics vs Nurix TherapeuticsAclaris Therapeutics vs Syndax PharmaceuticalsAclaris Therapeutics vs XencorAclaris Therapeutics vs Regeneron PharmaceuticalsAdd a third stock →
Full analyses: Aclaris Therapeutics · Medpaces
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100